Homburger advises BioVersys on IPO
Homburger advised BioVersys, a clinical-stage biopharmaceutical company domiciled in Basel, on all aspects of its Initial Public Offering (IPO).
The Initial Public Offer
The IPO was launched on SIX Swiss Exchange, comprising a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). Assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, the implied market capitalization of the company, has been approximately determined at CHF 212.9 m. The trading kick-off is planned for February 7, 2025. All global coordination and bookrunning aspects of the IPO were jointly managed by Citigroup, UBS and Stifel Europe. Mirabaud & Cie and Octavian acted as selling agents on the deal.
The team
Partners Dieter Gericke (pictured left) and Lorenzo Togni (pictured right) co-led the Homburger team, supported by associates Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all corporate / M&A and capital markets). Partner Luca Dal Molin and associate Kristina Martinovic (both IP / IT) assisted the team on intellectual property aspects; partner Reto Heuberger and associate Philippe Weber (both Tax) advised on taxation matters, while associate Jeremy Reichlin supported the team on employment and executive compensation aspects.
The company
BioVersys specialises in the identification, development and commercialization phases of novel antibacterial products for life-threatening infections caused by multi-drug resistant (MDR) bacteria. More specifically, studies on nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii and tuberculosis are amongst the company’s most advanced R&D programs.
Beyond its home biotech lab of Basel, BioVersys is also operative in Lille (France), Delaware (United States), and Guangzhou (China).